JP6814754B2 - Ｂａｃｅ１阻害剤ペプチド - Google Patents

Ｂａｃｅ１阻害剤ペプチド Download PDF

Info

Publication number
JP6814754B2
JP6814754B2 JP2017567791A JP2017567791A JP6814754B2 JP 6814754 B2 JP6814754 B2 JP 6814754B2 JP 2017567791 A JP2017567791 A JP 2017567791A JP 2017567791 A JP2017567791 A JP 2017567791A JP 6814754 B2 JP6814754 B2 JP 6814754B2
Authority
JP
Japan
Prior art keywords
pro
glu
val
gly
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017567791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523636A (ja
JP2018523636A5 (https=
Inventor
ボーチャンプ，ジェレミー
フレスクゴード，ペル−オーラ
キタス，エリック・アー
リャミチェフ，ビクター
パテル，ジガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Sequencing Solutions Inc
Original Assignee
F Hoffmann La Roche AG
Roche Nimblegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Nimblegen Inc filed Critical F Hoffmann La Roche AG
Publication of JP2018523636A publication Critical patent/JP2018523636A/ja
Publication of JP2018523636A5 publication Critical patent/JP2018523636A5/ja
Application granted granted Critical
Publication of JP6814754B2 publication Critical patent/JP6814754B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017567791A 2015-07-24 2016-07-21 Ｂａｃｅ１阻害剤ペプチド Expired - Fee Related JP6814754B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15178162 2015-07-24
EP15178162.2 2015-07-24
PCT/EP2016/067447 WO2017016982A1 (en) 2015-07-24 2016-07-21 Bace1 inhibitor peptides

Publications (3)

Publication Number Publication Date
JP2018523636A JP2018523636A (ja) 2018-08-23
JP2018523636A5 JP2018523636A5 (https=) 2019-08-29
JP6814754B2 true JP6814754B2 (ja) 2021-01-20

Family

ID=53776361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567791A Expired - Fee Related JP6814754B2 (ja) 2015-07-24 2016-07-21 Ｂａｃｅ１阻害剤ペプチド

Country Status (6)

Country Link
US (1) US10947272B2 (https=)
EP (1) EP3325500A1 (https=)
JP (1) JP6814754B2 (https=)
CN (1) CN107849092A (https=)
HK (1) HK1251593A1 (https=)
WO (1) WO2017016982A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CN120591368B (zh) * 2025-06-04 2026-04-21 武汉市米来生物科技有限公司 一种具有ace抑制活性的蛋黄多肽的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285892A1 (en) 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
US20070149763A1 (en) 2003-10-15 2007-06-28 Bristol-Myers Squibb Company Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
EP2119455A1 (en) 2004-04-08 2009-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tripartite raftophilic structures and their use
JP2008504329A (ja) 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 脂質ラフト内の病理プロセスに関係する障害を治療するためのステロイド由来の医薬組成物の使用
CN103608344B (zh) * 2011-06-07 2016-11-23 霍夫曼-拉罗奇有限公司 [1,3]噁嗪类
JP6134725B2 (ja) * 2011-10-14 2017-05-24 ジェネンテック， インコーポレイテッド Ｂａｃｅ１のペプチド阻害剤
CN104368009B (zh) * 2014-06-25 2018-01-30 中国人民解放军第二军医大学 一种双功能肽修饰的阿尔茨海默病靶向基因递释复合物及其制备方法
CN110051627A (zh) 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
WO2016044951A1 (en) 2014-09-25 2016-03-31 The Hospital For Sick Children Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
CN108064232B (zh) * 2014-11-28 2021-06-15 豪夫迈·罗氏有限公司 肽
US10208087B2 (en) * 2014-11-28 2019-02-19 Hoffmann-La Roche Inc. Peptides

Also Published As

Publication number Publication date
EP3325500A1 (en) 2018-05-30
WO2017016982A1 (en) 2017-02-02
JP2018523636A (ja) 2018-08-23
US20180179252A1 (en) 2018-06-28
HK1251593A1 (zh) 2019-02-01
CN107849092A (zh) 2018-03-27
US10947272B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
Oláh et al. Interactions of pathological hallmark proteins: Tubulin polymerization promoting protein/p25, β-amyloid, and α-synuclein
US7041784B2 (en) Apoptotic compounds
AU2007258387B2 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
JP2003525947A (ja) ガンマ−セクレターゼ阻害物質
WO2000077030A1 (en) Statine-derived tetrapeptide inhibitors of beta-secretase
JP6814754B2 (ja) Ｂａｃｅ１阻害剤ペプチド
WO2007145589A1 (en) Peptides that are capable of binding to amyloid-beta peptide.
US10208087B2 (en) Peptides
EP3224271B1 (en) Peptides
JP2009503027A (ja) アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
Piacentini et al. Transglutaminase 2 at the crossroads between cell death and survival
CN106661003A (zh) 具有三嗪‑哌嗪主链的α‑螺旋类似物及其制备方法
KR20220127877A (ko) 퇴행성 뇌질환 치료용 개선된 세포-투과성 변형 Ｐａｒｋｉｎ 재조합 단백질 및 이의 용도
JP7341451B2 (ja) タンパク質性化合物とその利用
Liu Development of Peptidomimetics Based on γ-AApeptide Molecular Scaffolds to Modulate Amyloid Peptide Aggregation
HK1236041B (zh) 肽
HK1236041A1 (en) Peptides
HK1253316B (zh) 肽
JP2002155043A (ja) アルギニナール誘導体及びアポトーシス阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201221

R150 Certificate of patent or registration of utility model

Ref document number: 6814754

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees